Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RG-101 plus oral agents in treatment-naïve genotype 1 and 4 chronic hepatitis C
2015-001535-21Phase 2Completed
- Sponsor
- Regulus Therapeutics
- Start
- May 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of RG-101 in hepatitis C virus infection and chronic hepatitis C (CHC) (2 cohorts), sponsored by Regulus Therapeutics. Primary endpoints: Sustained virologic response at 12 weeks post-treatment (SVR12) and Change in viral load at Week 17. Started May 2015; status: completed.
02
Drugs
RG-101
03
Conditions
hepatitis C virus infectionchronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-001535-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001535-21.